Market closed
Vertex Pharmaceuticals/$VRTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
$VRTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
5,400
Website
VRTX Metrics
BasicAdvanced
$102B
Market cap
-
P/E ratio
-$1.86
EPS
0.39
Beta
-
Dividend rate
Price and volume
Market cap
$102B
Beta
0.39
52-week high
$510.64
52-week low
$377.85
Average daily volume
1.6M
Financial strength
Current ratio
2.468
Quick ratio
2.083
Long term debt to equity
10.894
Total debt to equity
10.894
Interest coverage (TTM)
115.60%
Management effectiveness
Return on assets (TTM)
12.05%
Return on equity (TTM)
-2.99%
Valuation
Price to revenue (TTM)
9.631
Price to book
6.54
Price to tangible book (TTM)
7.46
Price to free cash flow (TTM)
-75.718
Growth
Revenue change (TTM)
10.06%
Earnings per share change (TTM)
-113.98%
3-year revenue growth (CAGR)
14.23%
3-year earnings per share growth (CAGR)
-39.33%
What the Analysts think about VRTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
VRTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VRTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VRTX News
AllArticlesVideos
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
Reuters·21 hours ago
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Business Wire·21 hours ago
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Business Wire·21 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $102B as of December 21, 2024.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 0 as of December 21, 2024.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.